<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2023-12-2-174-184</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1497</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL AND CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Влияние агониста фарнезоидного Х-рецептора на постпрандиальную липемию у крыс, получающих рацион, содержащий супрафизиологическую дозу жиров</article-title><trans-title-group xml:lang="en"><trans-title>Effect of a Farnesoid X-receptor Agonist on Postprandial Lipemia in Rats Fed a Supraphysiological Fat Dozes</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6852-3110</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алехин</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekhin</surname><given-names>Yu. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>394087, г. Воронеж, ул. Ломоносова, д. 114б</p></bio><bio xml:lang="en"><p>114b, Lomonosov str., Voronezh, 394087</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0650-0837</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>196084, г. Санкт-Петербург, ул. Черниговская, д. 5</p></bio><bio xml:lang="en"><p>5, Chernigovskaya str. St. Petersburg, 196084</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0666-7722</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Понамарёв</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ponamarev</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>196084, г. Санкт-Петербург, ул. Черниговская, д. 5</p></bio><bio xml:lang="en"><p>5, Chernigovskaya str. St. Petersburg, 196084</p></bio><email xlink:type="simple">psevdopyos@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8790-0540</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Паршин</surname><given-names>П. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Parshin</surname><given-names>P. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>394087, г. Воронеж, ул. Ломоносова, д. 114б</p></bio><bio xml:lang="en"><p>114b, Lomonosov str., Voronezh, 394087</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии» (ФГБНУ «ВНИВИПФиТ»)</institution></aff><aff xml:lang="en"><institution>All-russian Scientific Research Veterinary Institute Pathology, Pharmacology and Therapy</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Санкт-Петербургский государственный университет ветеринарной медицины» (СПбГУВМ)</institution></aff><aff xml:lang="en"><institution>Saint-Petersburg State University of Veterinary Medicine</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>05</month><year>2023</year></pub-date><volume>12</volume><issue>2</issue><fpage>174</fpage><lpage>184</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Алехин Ю.Н., Попова О.С., Понамарёв В.С., Паршин П.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Алехин Ю.Н., Попова О.С., Понамарёв В.С., Паршин П.А.</copyright-holder><copyright-holder xml:lang="en">Alekhin Y.N., Popova O.S., Ponamarev V.S., Parshin P.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1497">https://www.pharmjournal.ru/jour/article/view/1497</self-uri><abstract><sec><title>Введение</title><p>Введение. Одним из наиболее прогрессирующих направлений современного этапа развития биологии является углубление знаний о механизмах регуляции метаболических процессах, в частности о сигнальных молекулах, которые передают информацию клетке через ионные каналы и рецепторы ядерные, связанные с G-белком или с ферментативной активностью. Ядерный рецептор Farnesoid X receptor (FXR) в основном экспрессируется в печени и кишечнике, он регулирует ключевые гены, обеспечивающие процессы синтеза, транспорта и реабсорбции желчных кислот, а также участвует в метаболизме липидов и углеводов.</p></sec><sec><title>Цель</title><p>Цель. Оценить влияние агониста фарнезоидного Х-рецептора на постпрандиальную липемию у крыс, получающих рацион, содержащий супрафизиологическую дозу жиров.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведено экспериментальное проспективное контролируемое «неослепленное» рандомизированное исследование по изучению влияния агониста фарнезоидного Х-рецептора (обетихолевой кислоты) на постпрандиальную липемию у крыс, получающих рацион, содержащий супрафизиологическую дозу жиров.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Показано, что при оценке постпрандиальной липемии достаточно высокую информативность имеет пероральный тест на толерантность к супрафизиологическим дозам жира с определением исходных показателей липидного профиля и через 4 часа после нагрузки. Выявлено, что у животных, которые в течение 28 дней получали рацион, содержащий повышенное количество жира, наблюдался дисбаланс метаболизма липидов с активацией их всасывания в кишечнике, но «замедленной» реакцией механизмов промежуточного обмена липидов, что сопровождалось накоплением в крови голодных крыс триглицеридов, холестерина хиломикронов и ЛПНП. Через 4 часа после кормления у этих животных наблюдалось сверхнормальное повышение триглицеридов и холестерина.</p></sec><sec><title>Заключение</title><p>Заключение. Применение обетихолевой кислоты гармонизирует липидный обмен на фоне алиментарной жировой нагрузки за счет активации фарнезоидных Х-рецепторов кишечника и печени, что проявляется одновременным увеличением интенсивности процессов всасывания липидов и их промежуточного обмена. В результате исключается риск возникновения гиперхиломикронемии, гиперхолистеринемии и гипертриглицеридемии, снижается вероятность развития вторичной гиперлипедемии, толерантности к инсулину и функциональной перегрузки (или патологии) печени.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. One of the most progressive directions of the modern stage of development of biology is the deepening of knowledge about the mechanisms of regulation of metabolic processes, in particular about signal molecules that transmit information to the cell through ion channels and nuclear receptors associated with G-protein or with enzymatic activity. The nuclear Farnesoid X receptor (FXR) is mainly expressed in the liver and intestines, it regulates key genes that provide the processes of synthesis, transport and reabsorption of bile acids, and is also involved in the metabolism of lipids and carbohydrates.</p></sec><sec><title>Aim</title><p>Aim. To evaluate the effect of a farnesoid X receptor agonist on postprandial lipemia in rats fed a supraphysiological fat diet.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. An experimental, prospective, controlled, unblinded, randomized study was conducted to study the effect of a farnesoid X receptor agonist (obeticholic acid) on postprandial lipemia in rats receiving a diet containing a supraphysiological dose of fats.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. It has been shown that when assessing postprandial lipemia, an oral test for tolerance to supraphysiological doses of fat with the determination of the initial lipid profile parameters and 4 hours after exercise has a sufficiently high information content. It was found that in animals that received a diet containing an increased amount of fat for 28 days, there was an imbalance in lipid metabolism with activation of their absorption in the intestine, but a "slow" reaction of the mechanisms of intermediate lipid metabolism, which was accompanied by the accumulation of triglycerides and cholesterol in the blood of hungry rats, chylomicrons and LDL. At 4 hours post-feeding, these animals showed abnormal increases in triglycerides and cholesterol.</p></sec><sec><title>Conclusion</title><p>Conclusion. The use of obeticholic acid harmonizes lipid metabolism against the background of alimentary fat load, due to the activation of farnesoid X-receptors of the intestine and liver, which is manifested by a simultaneous increase in the intensity of lipid absorption processes and their intermediate metabolism. As a result, the risk of hyperchylomicronemia, hypercholesterolemia and hypertriglyceridemia is eliminated, the likelihood of developing secondary hyperlipedemia, insulin tolerance and functional overload (or pathology) of the liver is reduced.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>крысы</kwd><kwd>постпрандиальная липемия</kwd><kwd>агонисты фарнезоидного Х-рецептора</kwd><kwd>обетихоловая кислота</kwd><kwd>холестерин</kwd><kwd>триглицериды</kwd><kwd>хиломикроновый тест</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rats</kwd><kwd>postprandial lipemia</kwd><kwd>farnesoid X-receptor agonists</kwd><kwd>obeticholic acid</kwd><kwd>cholesterol</kwd><kwd>triglycerides</kwd><kwd>chylomicron test</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mazaira G. I., Zgajnar N. R., Lotufo C. M., Daneri-Becerra C., Sivils J. C., Soto O. B., Cox M. B., Galigniana A. M. D. The Nuclear Receptor Field: A Historical Overview and Future Challenges. Nucl. Recept. Res. 2018;5:101320. DOI: 10.11131/2018/101320.</mixed-citation><mixed-citation xml:lang="en">Mazaira G. I., Zgajnar N. R., Lotufo C. M., Daneri-Becerra C., Sivils J. C., Soto O. B., Cox M. B., Galigniana A. M. D. The Nuclear Receptor Field: A Historical Overview and Future Challenges. Nucl. Recept. Res. 2018;5:101320. DOI: 10.11131/2018/101320.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Blumberg B., Evans R. M. Orphan receptors – new ligands and new possibilities, Genes and Development. 1998;12:3149–3155. DOI: 10.1101/gad.12.20.3149.</mixed-citation><mixed-citation xml:lang="en">Blumberg B., Evans R. M. Orphan receptors – new ligands and new possibilities, Genes and Development. 1998;12:3149–3155. DOI: 10.1101/gad.12.20.3149.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ивашкин В. Т. Ядерные рецепторы и патология печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2010;20(4):7–15.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T. Nuclear receptors and liver pathology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2010;20(4):7–15. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Гриневич В. Б., Сас Е. И. Физиологические эффекты желчных кислот. РМЖ. Медицинское обозрение. 2017;2:87–91.</mixed-citation><mixed-citation xml:lang="en">Grinevich V. B., Sas E. I. Physiological effects of bile acids. Russian Medical Inquiry. 2017;2:87-91. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang L., Zhang H., Xiao D., Wei H., Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Computational and Structural Biotechnology Journal. 2021;19:2148–2159. DOI: 10.1016/j.csbj.2021.04.029.</mixed-citation><mixed-citation xml:lang="en">Jiang L., Zhang H., Xiao D., Wei H., Chen Y. Farnesoid X receptor (FXR): Structures and ligands. Computational and Structural Biotechnology Journal. 2021;19:2148–2159. DOI: 10.1016/j.csbj.2021.04.029.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Fiorucci S., Distrutti E., Ricci P., Giuliano V., Donini A., Baldelli F. Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets. 2014;18(12):1449–1459. DOI: 10.1517/14728222.2014.956087.</mixed-citation><mixed-citation xml:lang="en">Fiorucci S., Distrutti E., Ricci P., Giuliano V., Donini A., Baldelli F. Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets. 2014;18(12):1449–1459. DOI: 10.1517/14728222.2014.956087.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mudaliar S., Henry R. R., Sanyal A. J., Morrow L., Marschall H.-U., Kipnes M., Adorini L., Sciacca C. I., Clopton P., Castelloe E., Dillon P., Pruzanski M., Shapiro D. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574–582.e1. DOI: 10.1053/j.gastro.2013.05.042.</mixed-citation><mixed-citation xml:lang="en">Mudaliar S., Henry R. R., Sanyal A. J., Morrow L., Marschall H.-U., Kipnes M., Adorini L., Sciacca C. I., Clopton P., Castelloe E., Dillon P., Pruzanski M., Shapiro D. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2013;145(3):574–582.e1. DOI: 10.1053/j.gastro.2013.05.042.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Úbeda M., Lario M., Muñoz L., Borrero M. J., Rodríguez-Serrano M., Sánchez-Díaz A. M., Del Campo R., Lledó L., Pastor Ó., García-Bermejo L., Díaz D., Álvarez-Mon M., Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. Journal of Hepatology. 2016;64(5):1049–1057. DOI: 10.1016/j.jhep.2015.12.010.</mixed-citation><mixed-citation xml:lang="en">Úbeda M., Lario M., Muñoz L., Borrero M. J., Rodríguez-Serrano M., Sánchez-Díaz A. M., Del Campo R., Lledó L., Pastor Ó., García-Bermejo L., Díaz D., Álvarez-Mon M., Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. Journal of Hepatology. 2016;64(5):1049–1057. DOI: 10.1016/j.jhep.2015.12.010.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Боголюбова А. В., Майоров А. Ю., Мишина Е. Е., Шварц А. М., Белоусов П. В. Фарнезоидный рецептор (FXR) как потенциальная терапевтическая мишень при неалкогольной жировой болезни печени и ассоциированных заболеваниях. Сахарный диабет. 2017;20(6):449–453. DOI 10.14341/DM9374.</mixed-citation><mixed-citation xml:lang="en">Bogolyubova A. V., Maiorov A. Yu., Mishina E. E., Schwartz A. M., Belousov P. V. Farnesoid receptor (FXR) as a potential therapeutic target in non-alcoholic fatty liver disease and associated diseases. Diabetes Mellitus. 2017;20(6):449–453. (In Russ.) DOI: 10.14341/DM9374.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Антюфеева А. А., Лущик М. В. Создание экспериментальных моделей патологических состояний. Международный студенческий научный вестник. 2015;2(1):110–111.</mixed-citation><mixed-citation xml:lang="en">Antyufeeva A. A., Lushchik M. V. Creation of experimental models of pathological conditions. Mezhdunarodnyj studencheskij nauchnyj vestnik. 2015;2(1):110–111. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Янко Р. В., Чака Е. Г., Зинченко А. С., Сафонов С. Л., Левашов М. И. Особенности моделирования жирового гепатоза у крыс разного возраста на основе высококалорийного рациона. Ожирение и метаболизм. 2021;18(4):387–397. DOI: 10.14341/omet12789.</mixed-citation><mixed-citation xml:lang="en">Yanko R. V., Chaka E. G., Zinchenko A. S., Safonov S. L., Levashov M. I. Features of modeling fatty hepatosis in rats of different ages based on a high-calorie diet. Obesity and metabolism. 2021;18(4):387–397. (In Russ.) DOI: 10.14341/omet12789.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Seeni M. N., El Rabey H. A., Zamzami M. A., Alnefayee A. M. The hepatoprotective activity of olive oil and Nigella sativa oil against CCl&lt;sub&gt;4&lt;/sub&gt; induced hepatotoxicity in male rats. BMC Complement Altern Med. 2016;16(1):438. DOI: 10.1186/s12906-016-1422-4.</mixed-citation><mixed-citation xml:lang="en">Al-Seeni M. N., El Rabey H. A., Zamzami M. A., Alnefayee A. M. The hepatoprotective activity of olive oil and Nigella sativa oil against CCl&lt;sub&gt;4&lt;/sub&gt; induced hepatotoxicity in male rats. BMC Complement Altern Med. 2016;16:438. DOI: 10.1186/s12906-016-1422-4.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Мамедов М. Н., Каримов А. К. Вторичная гиперлипидемия: особенности проявления при различных соматических заболеваниях. Профилактическая медицина. 2021;24(3):105–110. DOI: 10.17116/profmed202124031105.</mixed-citation><mixed-citation xml:lang="en">Mamedov M. N., Karimov A. K. Secondary hyperlipidemia: features of manifestation in various somatic diseases. Profilakticheskaya medicina. 2021;24(3):105–110. (In Russ.) DOI: 10.17116/profmed202124031105.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Сандлер Ю. Г., Винницкая Е. В. Гиполипидемическая терапия у пациентов с хроническими заболеваниями печени: что нужно знать гастроэнтерологу. Эффективная фармакотерапия. 2021;17(28):36–45. DOI: 10.33978/2307-3586-2021-17-28-36-45.</mixed-citation><mixed-citation xml:lang="en">Sandler Yu. G., Vinnitskaya E. V. Lipid-lowering therapy in patients with chronic liver disease: what a gastroenterologist needs to know. Effektivnaya farmakoterapiya. 2021;17(28):36–45. (In Russ.) DOI: 10.33978/2307-3586-2021-17-28-36-45.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Xenoulis P. G., Steiner J. M. Lipid metabolism and hyperlipidemia in dogs. The Veterinary Journal. 2010;183:12–21. DOI: 10.1016/j.tvjl.2008.10.011.</mixed-citation><mixed-citation xml:lang="en">Xenoulis P. G., Steiner J. M. Lipid metabolism and hyperlipidemia in dogs. The Veterinary Journal. 2010;183:12–21. DOI: 10.1016/j.tvjl.2008.10.011.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Меньшиков В. В. Требования к аналитическим средствам лабораторного обеспечения внебольничной медицинской помощи. Клиническая лабораторная диагностика. 2001;9:5–6.</mixed-citation><mixed-citation xml:lang="en">Menshikov V. V. Requirements for analytical tools for laboratory support of out-of-hospital medical care. Russian Clinical Laboratory Diagnostics. 2001;9:5–6. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Julve J., Martín-Campos J. M., Escolà-Gil J. C., Blanco-Vaca F. Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics. Clin Chim Acta. 2016;455:134–148. DOI: 10.1016/j.cca.2016.02.004.</mixed-citation><mixed-citation xml:lang="en">Julve J., Martín-Campos J. M., Escolà-Gil J. C., Blanco-Vaca F. Chylomicrons: Advances in biology, pathology, laboratory testing, and therapeutics. Clin Chim Acta. 2016;455:134–148. DOI: 10.1016/j.cca.2016.02.004.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wallach J. B. Interpretation of Diagnostic Tests. 3rd ed. Boston: Little, Brown and Co.; 2010. 1143 p.</mixed-citation><mixed-citation xml:lang="en">Wallach J. B. Interpretation of Diagnostic Tests. 3rd ed. Boston: Little, Brown and Co.; 2010. 1143 p.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Войтенко Н. Г., Макарова М. Н., Зуева А. А. Вариабельность биохимических показателей крови и установление референсных интервалов в доклинических исследованиях. Сообщение 1: крысы. Лабораторные животные для научных исследований. 2020;1:47–53. DOI: 10.29296/2618723X-2020-01-06.</mixed-citation><mixed-citation xml:lang="en">Voitenko N. G., Makarova M. N., Zueva A. A. Variability of blood biochemical parameters and establishment of reference intervals in preclinical studies. Message 1: rats. Laboratory Animals for Science. 2020;1:47–53. (In Russ.) DOI: 10.29296/2618723X-2020-01-06.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Brewer H. B. Hypertriglyceridemia: changes in the plasma lipoproteins, associated with an increased risk of cardiovascular disease. The American Journal of Cardiology. 1999;83:3–12. DOI: 10.1016/s0002-9149(99)00308-2.</mixed-citation><mixed-citation xml:lang="en">Brewer H. B. Hypertriglyceridemia: changes in the plasma lipoproteins, associated with an increased risk of cardiovascular disease. The American Journal of Cardiology. 1999;83:3–12. DOI: 10.1016/s0002-9149(99)00308-2.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hirano T. Hypertriglyceridemia: concept and clinical significance. Nihon Rinsho. 2013;71(9):1519–1527.</mixed-citation><mixed-citation xml:lang="en">Hirano T. Hypertriglyceridemia: concept and clinical significance. Nihon Rinsho. 2013;71(9):1519–1527.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Алиев А. А. Липидный обмен и продуктивность жвачных животных. М.: Колос; 1980. 381 с.</mixed-citation><mixed-citation xml:lang="en">Aliev A. A. Lipid metabolism and productivity of ruminants. M.: Kolos; 1980. 381 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. Российские медицинские вести. 2010;2:72–78.</mixed-citation><mixed-citation xml:lang="en">Drapkina O. M., Gatsolaeva D. S., Ivashkin V. T. Non-alcoholic fatty liver disease as a component of the metabolic syndrome. Rossijskie medicinskie vesti. 2010;2:72–78. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ершова А. А., Аль Раши Д. О., Иванова А. А., Аксенова Ю. О., Мешков А. Н. Вторичные гиперлипидемии: этиология и патогенез. Российский кардиологический журнал. 2019;24(5):74–81.</mixed-citation><mixed-citation xml:lang="en">Ershova A. A., Al Rashi D. O., Ivanova A. A., Aksenova Yu. O., Meshkov A. N. Secondary hyperlipidemias: etiology and pathogenesis. Russian Journal of Cardiology. 2019;24(5):74–81. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Beisiegel U. Lipoprotein metabolism. Eur Hert J. 1998;19(Suppl A):A20–A23.</mixed-citation><mixed-citation xml:lang="en">Beisiegel U. Lipoprotein metabolism. Eur Hert J. 1998;19(Suppl A):A20–A23.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ганда О. Дислипопротеидемии. Эндокринология. М.: Практика; 1999. С. 447–461.</mixed-citation><mixed-citation xml:lang="en">Ganda O. Dyslipoproteinemias. Endocrinology. Moscow: Praktika; 1999. P. 447–461. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Shihabudeen M. S., Roy D., James J., Thirumurugan K. Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance. Mol. Cell Endocrinol. 2015;414:19–28. DOI: 10.1016/j.mce.2015.07.012.</mixed-citation><mixed-citation xml:lang="en">Shihabudeen M. S., Roy D., James J., Thirumurugan K. Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance. Mol. Cell Endocrinol. 2015;414:19–28. DOI: 10.1016/j.mce.2015.07.012.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kalugniy I. I., Markova D. S., Yashin A. V., Prusakov A. V., Ponamarev V. S., Andreeva N. L. Diagnosis of hepatopathy in Holstein cattle with metabolic disorders. IOP Conference Series: Earth and Environmental Science. 2021;723(2):022029. DOI: 10.1088/1755-1315/723/2/022029.</mixed-citation><mixed-citation xml:lang="en">Kalugniy I. I., Markova D. S., Yashin A. V., Prusakov A. V., Ponamarev V. S., Andreeva N. L. Diagnosis of hepatopathy in Holstein cattle with metabolic disorders. IOP Conference Series: Earth and Environmental Science. 2021;723(2):022029. DOI: 10.1088/1755-1315/723/2/022029.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Stepanov I. S., Kalugniy I. I., Markova D. S., Prusakov A. V., Ponamarev V. S., Lunegov A. M. Development and application of new methods of correction and prevention of metabolic diseases in Holstein cattle. IOP Conference Series: Earth and Environmental Science. 2021;723(2):022030. DOI: 10.1088/1755-1315/723/2/022030.</mixed-citation><mixed-citation xml:lang="en">Stepanov I. S., Kalugniy I. I., Markova D. S., Prusakov A. V., Ponamarev V. S., Lunegov A. M. Development and application of new methods of correction and prevention of metabolic diseases in Holstein cattle. IOP Conference Series: Earth and Environmental Science. 2021;723(2):022030. DOI: 10.1088/1755-1315/723/2/022030.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Baryshev V. A., Popova O. S., Ponamarev V. S. New methods for detoxification of heavy metals and mycotoxins in dairy cows. Online Journal of Animal and Feed Research. 2022;12(2):81–88. DOI: 10.51227/ojafr.2022.11.</mixed-citation><mixed-citation xml:lang="en">Baryshev V. A., Popova O. S., Ponamarev V. S. New methods for detoxification of heavy metals and mycotoxins in dairy cows. Online Journal of Animal and Feed Research. 2022;12(2):81–88. DOI: 10.51227/ojafr.2022.11.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
